CION Ameerpet
Removing the ovaries and fallopian tubes is the single most effective thing available for hereditary ovarian cancer risk, cutting it by around 80%. It also brings menopause forward, sometimes by a decade — and both halves of that deserve equal weight.
The operation is called salpingo-oophorectomy because it removes both the fallopian tubes (salpingo-) and the ovaries (-oophorectomy). That the tubes are included is not incidental — it reflects a significant shift in understanding of where these cancers actually start.
For decades the assumption was that high-grade serous ovarian cancer arose from the surface of the ovary. Detailed examination of tissue removed during risk-reducing surgery changed that. Pathologists found early precursor lesions with striking consistency in the fimbrial end of the fallopian tube — the fringed end that sits closest to the ovary — rather than in ovarian tissue. The current view is that a substantial proportion of what we call ovarian cancer begins in the tube.
This has two practical consequences. First, the tubes must be removed completely, right to where they meet the uterus, for the operation to achieve its benefit. Second, it is why the removed tissue undergoes a detailed sectioning protocol rather than a routine look — occult early lesions are found in a small percentage of women having risk-reducing surgery, and finding one changes what happens next.
Precursor lesions are found consistently at the fimbrial end of the fallopian tube rather than on the ovarian surface.
The tubes are taken right to the uterus. A residual stump undermines the point of the operation.
A sectioning protocol rather than a routine look, because occult early lesions are found in a small number of women.
Risk-reducing salpingo-oophorectomy lowers ovarian cancer risk by roughly eighty per cent — not one hundred. The reason is anatomical: the peritoneum, the membrane lining the abdominal cavity, shares an embryological origin with the ovarian surface, and it cannot be removed. A small residual risk of primary peritoneal cancer therefore remains for life. This is why the operation is described honestly as risk-reducing rather than risk-eliminating, and why persistent new abdominal symptoms after RRSO still warrant assessment rather than being dismissed on the grounds that the ovaries are gone. Source: NCCN Genetic/Familial High-Risk Assessment guidelines.
Timing is individualised and these are starting points for a conversation, not rules. Family history can shift them earlier.
| Situation | Usual timing discussed | Why |
|---|---|---|
| BRCA1 pathogenic variant | Around 35-40, after childbearing | BRCA1-related ovarian cancer occurs earlier and carries higher lifetime risk. |
| BRCA2 pathogenic variant | Around 40-45, after childbearing | BRCA2-related ovarian cancer tends to occur later; deferring costs less risk. |
| RAD51C, RAD51D, BRIP1 variants | Generally around 45-50 | Lower ovarian cancer risk than BRCA1, with later typical onset. |
| Lynch syndrome | Individualised, often with hysterectomy | Endometrial risk is usually the larger concern; managed together. |
| Family history, no variant found | Individualised on the family pattern | No gene to guide timing; the decision rests on the pedigree and personal preference. |
| Family not yet complete | Deferred, with surveillance discussed | Fertility is preserved; surveillance is offered honestly as a stopgap, not protection. |
*A family member diagnosed unusually young may shift the recommended timing earlier — commonly discussed as around five to ten years before the earliest diagnosis in the family.
This operation is genuinely effective and it genuinely takes something. A good decision requires both halves to be laid out properly.
This is the strongest intervention available for hereditary ovarian cancer risk, and nothing else comes close. There is no effective ovarian screening, so surveillance is not a comparable alternative — it is a way of waiting, not a way of protecting. For a BRCA1 carrier facing a lifetime risk of roughly 40 to 45 per cent, an eighty per cent reduction is a substantial change.
The benefit is not only in risk reduction but in what it removes from daily life: the persistent low-level watchfulness that many carriers describe, the anxiety around every episode of bloating, and the knowledge that no test is reliably watching for them in the meantime.
Removing both ovaries stops oestrogen production abruptly rather than over the years that natural menopause takes. The symptoms are consequently often more intense: hot flushes, night sweats, disturbed sleep, vaginal dryness, reduced libido, mood changes and difficulty concentrating, arriving suddenly rather than gradually.
For a woman having surgery at 37, this brings menopause forward by more than a decade. That is a substantial thing to absorb, and it deserves preparation rather than being presented as a footnote to the risk figures. Knowing what to expect, and having a plan in place before surgery, makes a real difference to how it is experienced.
Early loss of oestrogen accelerates bone density loss and is associated with increased cardiovascular risk over the long term. These are not reasons to avoid the surgery in a woman at high hereditary risk, but they are reasons the aftercare matters and should not be an afterthought.
Baseline bone density assessment where surgery is done young, attention to weight-bearing exercise, calcium and vitamin D, and — for most women without a contraindication — hormone replacement therapy, are all part of managing this properly rather than optional extras.
This causes considerable confusion, so it is worth stating clearly: for a woman without breast cancer who has RRSO before the natural age of menopause, hormone replacement therapy until around the average age of natural menopause is generally considered appropriate. It replaces hormones her body would otherwise still be making, rather than adding hormones beyond the normal span.
It does not undo the ovarian cancer risk reduction, because the tissue that would have given rise to the cancer has been removed. The situation differs for women with a personal history of breast cancer, where the decision is more complex and individualised. This should be discussed and planned before surgery, not raised afterwards.
RRSO ends the possibility of pregnancy with your own eggs, which is why it is generally recommended after childbearing is complete. This makes family planning and risk management a single conversation rather than two separate ones, and it is worth having early.
Where a carrier wants children but is approaching the recommended age for surgery, options including egg or embryo freezing can be discussed, as can pre-implantation genetic testing to avoid passing on the variant. Views on the latter differ widely and legitimately. See fertility and ovarian health.
In a small proportion of women, the detailed pathological examination of the removed tubes and ovaries finds an early cancer or a precursor lesion that nobody knew was there. This is uncommon, and it is one of the reasons the tissue is sectioned so thoroughly.
Where it happens, the finding is usually at a very early stage, which is a considerably better position than being diagnosed later with symptoms. Management moves to a gynaecologic-oncology pathway with a tumour-board discussion, and further treatment may or may not be needed depending on exactly what is found.
These are reasonable questions and any good team will expect them. If they cannot be answered clearly, that itself is informative.
Ask for your figures given your gene and family history rather than a general statement, and what residual peritoneal risk remains.
This should be decided before surgery, not raised afterwards. Ask what is planned and until what age.
Not routine for BRCA carriers, but sometimes discussed. Ask why if it is proposed, since it changes HRT options.
A detailed sectioning protocol rather than routine examination is what finds occult early lesions. Confirm it will be used.
A fair question with a specific answer that depends on your gene and age. Ask for the actual trade-off.
Aftercare should be planned, not left to be sorted out later. Ask who you contact when symptoms start.
New persistent abdominal symptoms after RRSO still warrant assessment. The residual peritoneal risk is small but real, and "my ovaries are gone" is not a reason to dismiss them.
For most carriers the question is not if but when — balanced against fertility, age and how surgical menopause will be managed. That is a conversation, not a form to sign.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. Genetic counselling is in-house; the surgery itself is coordinated with specialist partner centres.
This is usually keyhole surgery with a short recovery — often shorter than women expect for an operation with these consequences.
Confirmed genetic testing, a discussion of timing, and — importantly — an agreed plan for hormone replacement before rather than after the operation. Baseline bone density assessment where surgery is being done young. This is also the point to raise any questions about the uterus and about fertility.
Keyhole surgery through several small incisions, usually taking under an hour. Both fallopian tubes are removed completely, right to where they join the uterus, along with both ovaries. Most women go home the same day or the next.
The removed tissue undergoes a specific sectioning protocol designed to detect early lesions, rather than routine examination. This is what identifies the small number of occult cancers and precursor lesions, and it is worth confirming it will be done.
Physical recovery from laparoscopy is generally quick — light activity within about a week, full activity within two to four weeks. Shoulder-tip discomfort from the gas used is common and settles. The physical recovery is usually easier than expected; the hormonal adjustment is the part that takes longer.
Where HRT is planned, it usually begins promptly after surgery so that symptoms are prevented rather than treated once established. The regimen depends on whether the uterus has been retained. Adjustments in the first months are normal and expected.
Menopausal symptom review, bone health monitoring, and continued breast risk management, which does not change because of this operation and continues on its own pathway. Any new persistent abdominal symptoms should still be reported, because of the residual peritoneal risk.
The most common failure in this conversation is imbalance. Either the risk figures are presented so starkly that surgery feels like the only rational response, or surgical menopause is mentioned so briefly that women are unprepared for what follows. Both leave people making a major decision on incomplete information.
Your first consultation at CION is free and runs to about 45 minutes. Genetic counselling is delivered in-house here, which means the risk discussion, the timing question and the aftercare planning happen with a team that knows your result rather than across separate referrals. If you are still deciding, that is a perfectly good reason to come — the decision does not have to be made in the room.
We should be straightforward about who does what. Genetic counselling and BRCA and HRD testing are in-house at CION. The surgery itself — risk-reducing salpingo-oophorectomy — is coordinated with specialist gynaecologic-oncology partner centres and may be billed there. Where a woman does develop ovarian cancer, chemotherapy and maintenance therapy including PARP-inhibitor-class treatment are delivered in-house across 35+ centres.
The risk discussion, the testing and the plan handled by one team rather than spread across referrals.
Free and unhurried. Long enough to cover both the benefit and the cost properly rather than one at the expense of the other.
The menopause plan is agreed in advance rather than raised once symptoms have started.
RRSO is performed at specialist partner centres and may be billed there. We state that upfront.
By approximately eighty per cent, which makes it far and away the most effective intervention available for hereditary ovarian cancer risk. The reduction is not one hundred per cent because the peritoneum — the membrane lining the abdominal cavity — shares an embryological origin with the ovarian surface and cannot be removed, so a small residual risk of primary peritoneal cancer remains for life. This is why the operation is honestly described as risk-reducing rather than risk-eliminating, and why new persistent abdominal symptoms afterwards still warrant assessment.
Timing is individualised and depends mainly on which gene is involved and whether your family is complete. It is generally discussed from around 35 to 40 for BRCA1 carriers, because BRCA1-related ovarian cancer occurs earlier and carries higher lifetime risk, and from around 40 to 45 for BRCA2, where the disease tends to occur later. For variants in genes such as RAD51C, RAD51D and BRIP1 the usual discussion is later still. A relative diagnosed unusually young may shift the recommendation earlier — often discussed as five to ten years before the earliest diagnosis in the family.
For most women without a personal history of breast cancer, yes, and it is generally considered appropriate up to around the average age of natural menopause. The reasoning is straightforward: you are replacing hormones your body would still have been producing, rather than adding hormones beyond the normal span. It does not undo the ovarian cancer risk reduction, because the tissue that would have given rise to that cancer has been removed. The decision is more complex and individualised for women with a personal history of breast cancer. It should be planned before surgery rather than raised afterwards.
More abrupt than natural menopause, because oestrogen production stops immediately rather than declining over years. Hot flushes, night sweats, disturbed sleep, vaginal dryness, reduced libido, mood changes and difficulty concentrating can all arrive within days to weeks. The intensity varies considerably between women, and hormone replacement therapy prevents or substantially reduces most of these symptoms when started promptly. Knowing what to expect and having a plan in place before the operation genuinely changes how the first months are experienced.
Not routinely for BRCA carriers. Risk-reducing surgery for BRCA-related risk targets the ovaries and fallopian tubes, and the uterus is usually retained. Hysterectomy is sometimes discussed alongside it — for example where there is a separate gynaecological indication, or in Lynch syndrome where endometrial cancer risk is the larger concern. If hysterectomy is proposed, ask specifically why, because it also affects which type of hormone replacement therapy you would need afterwards. A woman who keeps her uterus needs a progestogen alongside oestrogen; one who does not, generally does not.
This happens in a small proportion of women, and it is one reason the removed tubes and ovaries undergo a detailed sectioning protocol rather than routine examination. Where an occult cancer or precursor lesion is found, it is usually at a very early stage — which is a substantially better position than being diagnosed later with symptoms. Management then moves to a gynaecologic-oncology pathway with a tumour-board discussion, and whether further treatment is needed depends on exactly what was found and how extensive it is.
You can, but it is important to understand what you would be choosing. Surveillance with CA-125 and transvaginal ultrasound has not been shown to reduce ovarian cancer deaths even in high-risk women, so it is a way of waiting rather than a way of protecting. It is legitimately offered to women deferring surgery for fertility reasons or while they decide, and it should be offered with that honest framing. Some women choose it knowingly and that is a valid decision — but it should not be presented as an equivalent alternative to an operation that reduces risk by eighty per cent.
The first consultation is free and runs to about 45 minutes, and genetic counselling and BRCA and HRD testing are delivered in-house at CION. The risk-reducing surgery itself is coordinated with specialist gynaecologic-oncology partner centres and may be billed there — we state that upfront rather than leaving it to be discovered later. Where a woman does develop ovarian cancer, chemotherapy and maintenance therapy including PARP-inhibitor-class treatment are delivered in-house at CION across more than 35 centres in Telangana and Andhra Pradesh.